Fair-Value Report — China Life Insurance (2628.HK)

China Life H trades at ~0.50x embedded value and ~4.9x earnings with a ~3.3% yield, after a record FY2025 (profit +44%, new-business value +35.7%). The smart-money tell is loud: Ping An — China's most sophisticated insurer — has been buying these exact H-shares on the open market, lifting its stake to ~15%. The catch is that the cheap P/EV is partly structural (China's sub-2% bond yields strain the return assumptions baked into "embedded value"), so this is a total-return / income idea with re-rating optionality, not a deep-value double.

1 · The insider signal that flagged this name

Why it qualifies — and why it's high-quality: a genuine, deliberate open-market buy by the most analytically rigorous insurer in the market, accumulated over months to a ~15% strategic position. This is the strongest class of "real-buyer" signal in the feed — a knowledgeable peer voting with size. Caveat: Ping An's motive is partly yield/asset-allocation (deploying insurance float into high-dividend equities under new accounting), so it validates the income case more than a near-term re-rating catalyst.

2 · Verified snapshot (price as of 2026-05-22, 16:08 HKT)

FX: 1 HKD ≈ RMB 0.923. Company financials in RMB; H-share price/multiples in HKD.

3 · Business

China's largest life insurer by premiums and assets (RMB 7.59tn), majority state-owned, with a vast agency and bancassurance distribution network. The economics: collect premiums, pay claims/benefits, and earn a spread on a giant investment portfolio — so results are highly sensitive to (a) China's interest-rate path and (b) domestic equity markets. FY2025 was a record (profit +44%, VNB +35.7%) on a strong A-share market and improved new-business margins, but that same equity sensitivity cuts both ways.

4 · Valuation

Method. A life insurer is valued on embedded value (EV) and the value of new business (VNB) — not a free-cash-flow DCF (insurer "FCF" is not meaningful). Primary anchor: P/EV; cross-checks: appraisal value (EV + a multiple of VNB), peer P/EV, dividend yield, and normalized P/E.

4a · P/EV scenarios (target P/EV × EV/share, EV/sh ≈ HKD 57.5)

4b · Appraisal value & the reverse read

Appraisal value = EV + (multiple × VNB). At zero credit for new business, AV already equals EV/share ≈ HKD 57.5; at a 10x VNB multiple it is ~HKD 75.

Reverse: at HKD 28.92 the market pays only ~50% of stated embedded value and assigns a negative multiple to all future new business. That is either (a) a verdict that EV is materially overstated — plausible, since China's 10-year yield near ~1.7% sits well below the ~4%+ long-run investment return assumed inside EV — or (b) a persistent H-share risk/illiquidity discount. The bull case is that this discount is too harsh against +44% profit, +35.7% VNB, and a sophisticated peer buying at ~HKD 29.60.

4c · Peer check — HK-listed insurers (2026-05-22)

P/E and dividend yield verified (stockanalysis.com, 2026-05-22). P/EV is approximate/illustrative: China Life's ~0.50x is computed from its stated EV; the mainland H-share cohort clusters ~0.4–0.7x while AIA commands a large premium for higher, more credible returns. Read-through: China Life sits mid-pack among mainland lifers — cheaper than Ping An, richer-yielding names like NCI/CPIC screen optically cheaper still — and the whole mainland cohort trades at a steep discount to AIA precisely because the market doubts the durability of their EV returns. China Life is therefore fairly-to-attractively valued within its peer set, not a stand-out bargain; the cohort-wide discount is the real debate.

5 · Conclusion & read-through to the insider buy

China Life H is genuinely cheap on absolute insurer metrics (0.50x EV, ~5x earnings, ~3.3% yield) and is compounding embedded value at a double-digit pace. Ping An's months-long accumulation to ~15% is a strong validating signal from the smartest domestic money — though it is as much a yield/asset-allocation play as a re-rating bet. Against that, the low multiple is partly structural: collapsing Chinese bond yields cast doubt on EV assumptions, earnings are equity-market-sensitive, and H-shares carry a chronic discount.

Rating: Moderate Buy / Accumulate — a total-return idea for income-oriented investors. Base fair value ~HKD 32 (+12%) plus a ~3.3% yield, with EV compounding providing a multi-year tailwind and a bull re-rating path to the low-40s if rates stabilize. Size it as a core income holding rather than a high-conviction deep-value position; the EV-credibility/rate overhang caps the upside and defines the risk.

6 · Key risks

• Interest-rate / spread risk — China's sub-2% 10-year yield pressures reinvestment and undermines the ~4%+ return assumptions inside embedded value; further declines hit both EV and earnings.
• EV-assumption credibility — if economic assumptions are optimistic, "real" EV is below stated, justifying part of the discount.
• Equity-market sensitivity — under IFRS 9/17, profit swings with A-share performance; FY2025's +44% partly reflects a strong market and can reverse.
• H/A discount & policy — H-shares persistently lag A-shares; state ownership means policy/strategic objectives can override minority-shareholder returns.
• Signal nuance — Ping An's buying is partly a yield/allocation strategy; it validates income, not necessarily an imminent catalyst.
• Data caveat — FY2025 EV/VNB are approximate pending the audited annual report; net-profit scope varies by source.